Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Sunlenca“
Suchtreffer
Begriffe & Kennungen
Sunlenca · 4.5 · 24 Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent ch
Eintrag öffnenSunlenca · 4.5 · 5 Medicinal product by Effects on concentrations. Recommendation concerning therapeutic areas Mean percent cha
Eintrag öffnenSunlenca · 4.5 · 6 Medicinal product by Effects on concentrations. Recommendation concerning therapeutic areas Mean percent cha
Eintrag öffnenSunlenca · 4.5 · 7 Medicinal product by Effects on concentrations. Recommendation concerning therapeutic areas Mean percent cha
Eintrag öffnenSunlenca · 4.5 · 8 b This study was conducted using lenacapavir 300 mg single dose administered orally. c Evaluated as a strong
Eintrag öffnenSunlenca · 4.5 · Co-administation of ritonavir may increase lenacapavir plasma concentrations. Tenofovir alafenamided,i,j (25 m
Eintrag öffnenSunlenca · 4.5 · Co-administation of ritonavir may increase lenacapavir plasma concentrations. Tenofovir alafenamided,i,j (25 m
Eintrag öffnenSunlenca · 4.5 · Effect of lenacapavir on the pharmacokinetics of other medicinal products
Eintrag öffnenSunlenca · 4.5 · Effect of lenacapavir on the pharmacokinetics of other medicinal products
Eintrag öffnenSunlenca · 4.5 · Effect of other medicinal products on the pharmacokinetics of lenacapavir
Eintrag öffnenSunlenca · 4.5 · Effect of other medicinal products on the pharmacokinetics of lenacapavir
Eintrag öffnenSunlenca · 4.5 · Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. Caution is advised if Sunlenca is co-admini
Eintrag öffnenSunlenca · 4.5 · Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. Caution is advised if Sunlenca is co-admini
Eintrag öffnenSunlenca · 4.5 · Lenacapavir is a substrate of CYP3A, P-gp and UGT1A1. Strong inducers of CYP3A, P-gp, and UGT1A1, such as rifa
Eintrag öffnenSunlenca · 4.5 · Lenacapavir is a substrate of CYP3A, P-gp and UGT1A1. Strong inducers of CYP3A, P-gp, and UGT1A1, such as rifa
Eintrag öffnenSunlenca · 4.5 · Medicinal product by Effects on concentrations. Recommendation concerning therapeutic areas Mean percent chang
Eintrag öffnenSunlenca · 4.5 · Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent chang
Eintrag öffnenSunlenca · 4.5 · Plasma concentration of triazolam may be increased when co-administered with lenacapavir. ANTICOAGULANTS Direc
Eintrag öffnenSunlenca · 4.5 · Plasma concentration of triazolam may be increased when co-administered with lenacapavir. ANTICOAGULANTS Direc
Eintrag öffnenSunlenca · 4.5 · Strong CYP3A4 inhibitors alone (e.g. voriconazole) or strong inhibitors of CYP3A4 and P-gp together (e.g. cobi
Eintrag öffnen